Cargando…

National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points

INTRODUCTION: The National Institute on Aging (NIA) provides funding to academic researchers and small businesses working in the Alzheimer's Disease (AD) and AD‐related dementia (ADRD) fields to help commercialize their products. The NIA uses Small Business Innovation Research (SBIR) awards to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghazarian, Armineh L, Haim, Todd, Sauma, Samir, Katiyar, Pragati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291195/
https://www.ncbi.nlm.nih.gov/pubmed/34374496
http://dx.doi.org/10.1002/alz.12392
_version_ 1784749088354336768
author Ghazarian, Armineh L
Haim, Todd
Sauma, Samir
Katiyar, Pragati
author_facet Ghazarian, Armineh L
Haim, Todd
Sauma, Samir
Katiyar, Pragati
author_sort Ghazarian, Armineh L
collection PubMed
description INTRODUCTION: The National Institute on Aging (NIA) provides funding to academic researchers and small businesses working in the Alzheimer's Disease (AD) and AD‐related dementia (ADRD) fields to help commercialize their products. The NIA uses Small Business Innovation Research (SBIR) awards to bridge the funding gap in the diagnostic, therapeutic, and care interventions areas, enabling startups to reach key value inflection points to achieve scientific milestones. METHODS: Only publicly available information is reported. The National Institutes of Health Report Portfolio Online Reporting Tool database and the commercial database Global Data, were used to track the progress of companies that received SBIR or Small Business Technology Transfer (STTR) funding from the NIA. RESULTS: Since 2008, the NIA has awarded $280 million—including $207 million from fiscal year (FY) 2015 to FY 2019—in new small business program awards for AD/ADRD research. DISCUSSION: NIA seed capital and mentoring programs are critical resources to help small businesses reach key value inflection points and advance their research from concept to commercialization.
format Online
Article
Text
id pubmed-9291195
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92911952022-07-20 National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points Ghazarian, Armineh L Haim, Todd Sauma, Samir Katiyar, Pragati Alzheimers Dement Review Article INTRODUCTION: The National Institute on Aging (NIA) provides funding to academic researchers and small businesses working in the Alzheimer's Disease (AD) and AD‐related dementia (ADRD) fields to help commercialize their products. The NIA uses Small Business Innovation Research (SBIR) awards to bridge the funding gap in the diagnostic, therapeutic, and care interventions areas, enabling startups to reach key value inflection points to achieve scientific milestones. METHODS: Only publicly available information is reported. The National Institutes of Health Report Portfolio Online Reporting Tool database and the commercial database Global Data, were used to track the progress of companies that received SBIR or Small Business Technology Transfer (STTR) funding from the NIA. RESULTS: Since 2008, the NIA has awarded $280 million—including $207 million from fiscal year (FY) 2015 to FY 2019—in new small business program awards for AD/ADRD research. DISCUSSION: NIA seed capital and mentoring programs are critical resources to help small businesses reach key value inflection points and advance their research from concept to commercialization. John Wiley and Sons Inc. 2021-08-10 2022-02 /pmc/articles/PMC9291195/ /pubmed/34374496 http://dx.doi.org/10.1002/alz.12392 Text en © 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Article
Ghazarian, Armineh L
Haim, Todd
Sauma, Samir
Katiyar, Pragati
National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points
title National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points
title_full National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points
title_fullStr National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points
title_full_unstemmed National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points
title_short National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points
title_sort national institute on aging seed funding enables alzheimer's disease startups to reach key value inflection points
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291195/
https://www.ncbi.nlm.nih.gov/pubmed/34374496
http://dx.doi.org/10.1002/alz.12392
work_keys_str_mv AT ghazarianarminehl nationalinstituteonagingseedfundingenablesalzheimersdiseasestartupstoreachkeyvalueinflectionpoints
AT haimtodd nationalinstituteonagingseedfundingenablesalzheimersdiseasestartupstoreachkeyvalueinflectionpoints
AT saumasamir nationalinstituteonagingseedfundingenablesalzheimersdiseasestartupstoreachkeyvalueinflectionpoints
AT katiyarpragati nationalinstituteonagingseedfundingenablesalzheimersdiseasestartupstoreachkeyvalueinflectionpoints